| abstract |
The present invention provides compositions and kits and methods based on selective antagonists of either CXCR2 or both CXCR1 and CXCR2 useful for treating inflammatory disorders. In a preferred embodiment, the selective antagonist of either CXCR2 or both CXCR1 and CXCR2 is referred to herein as Compound I and is 2-hydroxy-N, N-dimethyl-3-[[2-[[ 1 (R) -5-methyl-2-furanyl) propyl] amino] -3,4-dioxo-1-cyclobuten-1-yl] amino] benzamide, or a pharmaceutically acceptable salt thereof. |